Latest guidelines on blood pressure
Reading File
Searching the Web
2025 2026 blood pressure hypertension guidelines ACC AHA ESC
Searching PubMed
"hypertension" AND "guidelines"
Reading Article
Reading Article
Reading Web Page
2025 ACC AHA hypertension blood pressure guidelines classification treatment targets
Here is a comprehensive, up-to-date summary of the current blood pressure guidelines:
Blood Pressure Guidelines: 2025 ACC/AHA & 2024 ESC
The Two Major Guidelines
There are now two current guidelines to know:
- 2025 AHA/ACC Guideline (PMID: 40811516) - published October 2025, replaces the 2017 guideline. Endorsed by 13 professional societies.
- 2024 ESC Guideline (PMID: 39210715) - published October 2024, replaces the 2018 ESC guideline.
BP Classification
| Category | ACC/AHA 2025 (SBP/DBP) | ESC 2024 (SBP/DBP) |
|---|---|---|
| Normal | <120/<80 | <120/<80 |
| Elevated / High-normal | 120-129 / <80 | 120-129 / 80-84 |
| Stage 1 / Grade 1 | 130-139 / 80-89 | 140-159 / 90-99 |
| Stage 2 / Grade 2 | ≥140 / ≥90 | 160-179 / 100-109 |
| Stage 3 / Grade 3 | - | ≥180 / ≥110 |
| Hypertensive crisis | ≥180/120 + organ damage | same concept |
Note: The ACC/AHA still uses its 130/80 threshold for defining hypertension (from 2017), while the ESC uses 140/90 as its diagnostic threshold. Many individuals labeled "Stage 1 hypertensive" in the US are classified as "elevated" or "high-normal" in Europe.
Treatment Targets
2025 ACC/AHA:
- Universal target: <130/80 mmHg for all adults
- Encourage SBP <120 mmHg when feasible to maximize CVD risk reduction
- Exceptions: institutionalized/nursing home patients, limited life expectancy, pregnancy
2024 ESC:
- Primary target: <140/80 mmHg for most patients
- Tighter targets by age (if well tolerated):
- Age 18-64: 120-129 / 70-79 mmHg
- Age 65-79: 130-139 mmHg (systolic)
- Age ≥80 or frail: 140-150 mmHg (systolic)
When to Start Drug Therapy
2025 ACC/AHA:
- Start immediately if BP ≥140/90 mmHg (regardless of risk)
- Start immediately if BP ≥130/80 mmHg with: established CVD, prior stroke, diabetes, CKD, or 10-year CVD risk ≥7.5% (using the new PREVENT™ equation, which replaces the Pooled Cohort Equation)
- For lower-risk adults with BP 130-139/80-89: start drugs if BP persists after 3-6 months of lifestyle therapy
2024 ESC:
- Start immediately in Grade 2-3 hypertension (≥160/100) and in high-risk Grade 1
- 3-6 month lifestyle trial before drugs in low-risk Grade 1 (<150/95)
- High-normal BP (130-139/80-89): drugs only if established coronary artery disease
First-Line Drug Therapy
All three major guidelines agree on the same four first-line drug classes:
- ACE inhibitors (ACEi)
- Angiotensin receptor blockers (ARBs)
- Long-acting dihydropyridine calcium channel blockers (DHP-CCB)
- Thiazide/thiazide-like diuretics
Key 2025 ACC/AHA updates:
- First-line selection is now race-neutral - prior race-based recommendations (e.g., preferring CCBs in Black patients) have been removed. Evidence showed race has limited predictive value for antihypertensive response.
- Stage 2 hypertension (≥140/90): prefer single-pill dual-class fixed-dose combinations to improve adherence and speed BP control.
Key New Additions in 2025 ACC/AHA
| Change | Details |
|---|---|
| Risk calculator | PREVENT™ replaces the Pooled Cohort Equation |
| Race neutrality | No race-based drug selection |
| Dementia prevention | Intensive BP lowering (target <130 mmHg) now shown to reduce risk of cognitive decline and dementia |
| Combination pills | Preferred upfront for Stage 2 |
| Living document | Designated as a "living guideline" with planned ongoing updates |
| Renal denervation (RDN) | Incorporated for selected patients with resistant hypertension (SBP 140-180, DBP ≥90, on ≥4 drugs including an MRA) |
Resistant Hypertension
All guidelines define resistant hypertension as failure to reach target BP on ≥3 agents (including a diuretic) at optimal doses. Management across all guidelines:
- Confirm with ambulatory (ABPM) or home BP monitoring
- Exclude pseudo-resistance (poor adherence, white coat effect, therapeutic inertia)
- Rule out secondary causes (especially primary aldosteronism)
- Optimize diuretic, add spironolactone (MRA) as next step
- Renal denervation (FDA-approved 2023): now Class IIb in all three guidelines for carefully selected patients
Lifestyle Modifications (All Guidelines)
These remain foundational regardless of drug therapy:
- Weight loss (target BMI <25)
- DASH or Mediterranean diet, low sodium (<1.5 g/day per AHA)
- Physical activity - 150 min/week moderate aerobic exercise
- Alcohol reduction - ≤1 drink/day for women, ≤2 for men
- Smoking cessation
- Stress reduction
Sources:
- 2025 ACC/AHA Hypertension Guideline (Circulation 2025;152:e114-e218; PMID 40811516)
- 2024 ESC Hypertension Guideline (Eur Heart J 2024; PMID 39210715)
- Trans-Atlantic Comparison of 2025 AHA/ACC vs ESC/ESH
This is a shared conversation. Sign in to Orris to start your own chat.